Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin ophthalmic - Santen SAS

Drug Profile

Ciclosporin ophthalmic - Santen SAS

Alternative Names: Ciclosporin - Santen SAS; Cyclokat; DE 076B; DE 076C; Ikervis; Nova 22007; Vekacia; Verkazia

Latest Information Update: 17 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novagali Pharma
  • Developer Santen Pharmaceutical; Santen S.A.S.
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Allergic conjunctivitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dry eyes
  • Registered Allergic conjunctivitis

Most Recent Events

  • 29 Apr 2019 Santen SAS initiates enrolment in a phase III trial in Dry eyes in Czech Republic (Ophthalmic) (EudraCT2017-002660-41)
  • 10 Jul 2018 Registered for Allergic conjunctivitis (In adolescents, In children) in Norway, Liechtenstein, Iceland, European Union (Ophthalmic)
  • 24 Jul 2017 Committee for Medicinal Products for HumanUse (CHMP) recommends approval of ciclosporin for Allergic conjunctivitis (In children, In adolescents) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top